JP2020511136A - 免疫調節性融合タンパク質およびその使用 - Google Patents

免疫調節性融合タンパク質およびその使用 Download PDF

Info

Publication number
JP2020511136A
JP2020511136A JP2019550246A JP2019550246A JP2020511136A JP 2020511136 A JP2020511136 A JP 2020511136A JP 2019550246 A JP2019550246 A JP 2019550246A JP 2019550246 A JP2019550246 A JP 2019550246A JP 2020511136 A JP2020511136 A JP 2020511136A
Authority
JP
Japan
Prior art keywords
fusion protein
seq
amino acid
acid sequence
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019550246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511136A5 (https=
Inventor
シャノン ケー． オダ，
シャノン ケー． オダ，
フィリップ ディー． グリーンバーグ，
フィリップ ディー． グリーンバーグ，
トーマス エム． シュミット，
トーマス エム． シュミット，
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター, フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2020511136A publication Critical patent/JP2020511136A/ja
Publication of JP2020511136A5 publication Critical patent/JP2020511136A5/ja
Priority to JP2022097950A priority Critical patent/JP7465306B2/ja
Priority to JP2024000159A priority patent/JP2024019732A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019550246A 2017-03-17 2018-03-16 免疫調節性融合タンパク質およびその使用 Pending JP2020511136A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022097950A JP7465306B2 (ja) 2017-03-17 2022-06-17 免疫調節性融合タンパク質およびその使用
JP2024000159A JP2024019732A (ja) 2017-03-17 2024-01-04 免疫調節性融合タンパク質およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762473282P 2017-03-17 2017-03-17
US62/473,282 2017-03-17
US201862629663P 2018-02-12 2018-02-12
US62/629,663 2018-02-12
PCT/US2018/022998 WO2018170475A1 (en) 2017-03-17 2018-03-16 Immunomodulatory fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022097950A Division JP7465306B2 (ja) 2017-03-17 2022-06-17 免疫調節性融合タンパク質およびその使用

Publications (2)

Publication Number Publication Date
JP2020511136A true JP2020511136A (ja) 2020-04-16
JP2020511136A5 JP2020511136A5 (https=) 2021-04-15

Family

ID=61911694

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019550246A Pending JP2020511136A (ja) 2017-03-17 2018-03-16 免疫調節性融合タンパク質およびその使用
JP2022097950A Active JP7465306B2 (ja) 2017-03-17 2022-06-17 免疫調節性融合タンパク質およびその使用
JP2024000159A Withdrawn JP2024019732A (ja) 2017-03-17 2024-01-04 免疫調節性融合タンパク質およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022097950A Active JP7465306B2 (ja) 2017-03-17 2022-06-17 免疫調節性融合タンパク質およびその使用
JP2024000159A Withdrawn JP2024019732A (ja) 2017-03-17 2024-01-04 免疫調節性融合タンパク質およびその使用

Country Status (8)

Country Link
US (2) US11725210B2 (https=)
EP (1) EP3595706A1 (https=)
JP (3) JP2020511136A (https=)
CN (2) CN119409836A (https=)
AU (1) AU2018236461B2 (https=)
CA (1) CA3055784A1 (https=)
MX (2) MX2019010812A (https=)
WO (1) WO2018170475A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN119409836A (zh) 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
AU2019335014A1 (en) * 2018-09-05 2021-03-25 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN113166226B (zh) 2018-09-28 2025-06-27 纪念斯隆-凯特琳癌症中心 表达显性负性fas的免疫应答细胞及其用途
GB2569692A (en) * 2018-10-30 2019-06-26 Tc Biopharm Ltd T cell antigen receptor chimera
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP3897690A4 (en) * 2018-12-19 2022-09-28 Cue Biopharma, Inc. T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
KR20220030205A (ko) * 2019-02-08 2022-03-10 디앤에이 투포인토 인크. 면역 세포의 트랜스포존 기반 변형
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy
US20220372105A1 (en) * 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
KR20220062305A (ko) * 2019-09-16 2022-05-16 맥마스터 유니버시티 키메라 공자극 수용체 및 이의 방법 및 용도
CN110790842B (zh) * 2019-11-25 2021-03-30 贵州康钦承平生物科技有限公司 一种FasL-CAR融合蛋白和表达融合蛋白的T细胞及其制备方法和应用
EP4087594A4 (en) * 2020-01-06 2024-02-28 Memorial Sloan Kettering Cancer Center Novel dominant negative fas polypeptides, cells comprising thereof and uses thereof
WO2021183795A1 (en) * 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
US20230133554A1 (en) 2020-04-09 2023-05-04 Autolus Limited Molecule
JP7755597B2 (ja) * 2020-04-09 2025-10-16 オートラス リミテッド 細胞
GB202101491D0 (en) * 2021-02-03 2021-03-17 Autolus Ltd Molecule
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
US20230203125A1 (en) * 2020-05-22 2023-06-29 Chongqing Precision Biotech Co., Ltd. Fusion protein for reversing tumor microenvironment and use thereof
EP4182338A1 (en) 2020-07-17 2023-05-24 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
WO2022266192A1 (en) 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
JP2024541501A (ja) * 2021-11-25 2024-11-08 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ Ｃｄ９５ポリペプチド
US20250144211A1 (en) * 2022-02-07 2025-05-08 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding
EP4499680A1 (en) * 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
TW202402798A (zh) * 2022-05-23 2024-01-16 美商艾費尼Ｔ醫療公司 對新抗原具特異性之結合蛋白與工程化細胞及其用途
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
WO2024046468A1 (en) * 2022-09-02 2024-03-07 Nanjing Legend Biotech Co., Ltd. Fusion proteins targeting lysosomal degradation pathway
KR20240095012A (ko) * 2022-11-29 2024-06-25 (주) 테라베스트 Cd137 세포외 도메인을 포함하는 융합단백질, 이를 발현하는 면역세포 및 이의 용도
WO2024193714A1 (zh) * 2023-03-23 2024-09-26 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
WO2025081123A1 (en) 2023-10-12 2025-04-17 Fred Hutchinson Cancer Center Methods and compositions for improving t cell immunotherapy
WO2025117773A2 (en) * 2023-11-30 2025-06-05 Affini-T Therapeutics, Inc. Compositions and methods for treating neoplasia
EP4599843A1 (en) 2024-02-09 2025-08-13 Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau Car and modified cd200r combination
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999A (en) 1841-03-12 Improvement in seed-planters
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
CA2204183A1 (en) 1994-11-01 1996-05-09 Andrew Lawrence Feldhaus Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013192294A1 (en) * 2012-06-20 2013-12-27 Boston 3T Biotechnologies, Inc. Cellular therapies for treating and preventing cancers and other immune system disorders
WO2014106839A1 (en) 2013-01-01 2014-07-10 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
EP2943565B1 (en) 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
CN103965361B (zh) 2013-02-06 2018-10-30 上海细胞治疗工程技术研究中心集团有限公司 一种t细胞信号的嵌合分子转换器及其用途
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
PL3560953T3 (pl) 2014-12-24 2024-05-13 Autolus Limited Komórka
WO2016118780A1 (en) 2015-01-21 2016-07-28 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
DK3909972T5 (da) 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2017184901A1 (en) 2016-04-20 2017-10-26 Fred Hutchinson Cancer Research Center Immunomodulatory il2r fusion proteins and uses thereof
CN119409836A (zh) 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
WO2019061012A1 (zh) 2017-09-26 2019-04-04 南京凯地生物科技有限公司 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用
CN110330567B (zh) 2019-07-02 2020-11-06 南京凯地生物科技有限公司 双特异性嵌合抗原受体t细胞，其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Also Published As

Publication number Publication date
US11725210B2 (en) 2023-08-15
CN119409836A (zh) 2025-02-11
US12365906B2 (en) 2025-07-22
MX2019010812A (es) 2019-12-11
AU2018236461A1 (en) 2019-09-19
MX2024000006A (es) 2024-02-20
JP7465306B2 (ja) 2024-04-10
US20200009190A1 (en) 2020-01-09
JP2024019732A (ja) 2024-02-09
CN110621335A (zh) 2019-12-27
US20240218379A1 (en) 2024-07-04
CN110621335B (zh) 2025-06-03
EP3595706A1 (en) 2020-01-22
AU2018236461B2 (en) 2025-03-27
JP2022113880A (ja) 2022-08-04
CA3055784A1 (en) 2018-09-20
WO2018170475A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
JP7465306B2 (ja) 免疫調節性融合タンパク質およびその使用
JP7441201B2 (ja) 免疫調節性融合タンパク質およびその使用
US20190127435A1 (en) Immunomodulatory il2r fusion proteins and uses thereof
JP2024502170A (ja) 癌のための改良された養子細胞移植療法
JP2024502170A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221005